Skip to main content

GlipiZIDE XL Side Effects

Generic name: glipizide

Medically reviewed by Last updated on Jun 21, 2021.

Note: This document contains side effect information about glipizide. Some dosage forms listed on this page may not apply to the brand name GlipiZIDE XL.

Applies to glipizide: oral tablets.

Side effects include:

Conventional tablets: Nausea, anorexia, vomiting, pyrosis, gastralgia, diarrhea, constipation.

Extended-release tablets: Dizziness, diarrhea, nervousness, tremor, hypoglycemia, flatulence.

Glipizide (the active ingredient contained in GlipiZIDE XL) metformin hydrochloride fixed combination: Upper respiratory tract infection, diarrhea, dizziness, hypertension, nausea/vomiting, musculoskeletal pain, headache, abdominal pain, urinary tract infection.

For Healthcare Professionals

Applies to glipizide: compounding powder, oral tablet, oral tablet extended release.


The more commonly reported side effects have included dizziness, diarrhea, nervousness, tremor, hypoglycemia, and flatulence.[Ref]


Disulfiram-like reactions have been reported with sulfonylureas. Clinical experience has shown this drug to have a low incidence of disulfiram-like alcohol reactions.[Ref]

Common (1% to 10%): Hypoglycemia

Uncommon (less than 1%): Thirst

Frequency not reported: Disulfiram like reactions, hepatic porphyria, hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), elevation of LDH[Ref]


Frequency not reported: Leucopenia, agranulocytosis, thrombocytopenia, aplastic anemia, hemolytic anemia, pancytopenia[Ref]


Common (1% to 10%): Syncope

Uncommon (less than 1%): Arrhythmia, flushing, hypertension[Ref]


Frequency not reported: Impaired hepatic function, hepatitis, jaundice, mild to moderate ALT, LDH, alkaline phosphatase elevations

Postmarketing reports: Cholestatic and hepatocellular forms of liver injury accompanied by jaundice[Ref]


Dermatologic side effects frequently disappear with continued therapy. Photosensitivity has been reported with other sulfonylureas.[Ref]

Common (1% to 10%): Sweating, pruritus

Uncommon (less than 1%): Rash, urticaria

Frequency not reported: Rash, erythema, morbilliform or maculopapular eruptions, urticaria, pruritus, eczema[Ref]


Common (1% to 10%): Nausea, diarrhea, constipation, gastralgia, vomiting, flatulence, dyspepsia

Uncommon (less than 1%): Anorexia, trace blood in stool

Frequency not reported: Gastrointestinal irritation, gastrointestinal bleeding

Postmarketing reports: Abdominal pain[Ref]

Gastrointestinal side effects appear to be dose-related and may disappear on division or reduction of dosage.[Ref]


Common (1% to 10%): Polyuria

Uncommon (less than 1%): Dysuria[Ref]


Common (1% to 10%): Arthralgia, leg cramps, myalgia[Ref]

Nervous system

Common (1% to 10%): Headache, dizziness, nervousness, tremors, paresthesia, hypesthesia

Uncommon (less than 1%): Migraine

Frequency not reported: Drowsiness[Ref]


Common (1% to 10%): Blurred vision

Uncommon (less than 1%): Pain in the eye, conjunctivitis, retinal hemorrhage

Frequency not reported: Diplopia, abnormal vision, visual impairment, decreased vision[Ref]


Common (1% to 10%): Asthenia, pain

Uncommon (less than 1%): Chills, edema

Frequency not reported: Vertigo, malaise[Ref]


Common (1% to 10%): Insomnia, anxiety, depression

Frequency not reported: Confusion[Ref]


Common (1% to 10%): Rhinitis

Uncommon (less than 1%): Pharyngitis, dyspnea[Ref]


Frequency not reported: Mild to moderate BUN and creatinine elevations

More about GlipiZIDE XL (glipizide)

Patient resources

Other brands

Glucotrol, Glucotrol XL

Professional resources

Related treatment guides


1. "Product Information. Glucotrol (glipizide)." Pfizer U.S. Pharmaceuticals (2002):

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

4. Feinglos MN, Lebovitz HE "Long-term safety and efficacy of glipizide." Am J Med 75 (1983): 60-6

5. Moder KG, Schwenk NM "A coproporphyria-like syndrome induced by glipizide." Mayo Clin Proc 66 (1991): 312-6

6. Asplund K, Wiholm BE, Lundman B "Severe hypoglycaemia during treatment with glipizide." Diabet Med 8 (1991): 726-31

7. Brogden RN, Heel RC, Pakes GE, Speight TM, Avery GS "Glipizide: a review of its pharmacological properties and therapeutic use." Drugs 18 (1979): 329-53

8. Lebovitz HE "Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use." Pharmacotherapy 5 (1985): 63-77

9. Prendergast BD "Glyburide and glipizide, second-generation oral sulfonylurea hypoglycemic agents." Clin Pharm 3 (1984): 473-85

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.